跳至主要内容
临床试验/NCT02448784
NCT02448784已完成不适用

Post-marketing Surveillance of Donepezil Hydrochloride - Investigation of Long Term Safety and Efficacy of Aricept as Well as Its Proper Use Information in Patients With Dementia With Lewy Bodies.

Eisai Co., Ltd.0 个研究点目标入组 591 人开始时间: 2015年4月20日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
591
主要终点
Mean Mini-Mental State Examination (MMSE) score

研究概览

简要总结

To investigate long term safety (especially about Parkinsonism) and efficacy of donepezil hydrochloride in clinical practice as well as its proper use information in participants with DLB.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Naive participants diagnosed as DLB

排除标准

  • Participants with a history of donepezil hydrochloride product administration in the past
  • Participants who have already been registered in this surveillance
  • Participants with a history of hypersensitivity to any ingredients of donepezil hydrochloride or piperidine derivatives

研究组 & 干预措施

Participants with DLB

Participants with DLB who will receive donepezil hydrochloride per approved label.

干预措施: Donepezil Hydrochloride (Drug)

结局指标

主要结局

Mean Mini-Mental State Examination (MMSE) score

时间窗: At Week 52

Mean Revised Hasegawa's Dementia Scale (HDS-R) score

时间窗: At Week 52

次要结局

  • Number of participants with adverse events (AEs) /adverse drug reactions (ADRs)(From Week 0 to Week 52)

研究者

申办方类型
Industry
责任方
Sponsor

相似试验

Post-marketing Surveillance of Donepezil... | 临床试验